Argenica Therapeutics Limited (ASX:AGN)

Argenica Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-7.17	-5.48	-4.82	-4.09	-1.03
Stock-Based Compensation	0.11	0.14	0.46	0.43	0.27
Change in Accounts Receivable	-0.03	-0.23	-0.07	-0	-0.09
Change in Accounts Payable	1.47	0.45	0.46	0.29	-0.2
Change in Unearned Revenue	-0.09	0.05	0.66	-	-
Change in Other Net Operating Assets	0.01	0.02	0.01	0.02	0.01
Operating Cash Flow	-5.7	-5.06	-3.3	-3.36	-1.05
Investment in Securities	-	0.05	-0.05	-	-
Investing Cash Flow	-	0.05	-0.05	-	-
Issuance of Common Stock	0.35	11.63	3.73	5.13	7.85
Other Financing Activities	-	-	0	0	0
Financing Cash Flow	0.35	11.63	3.73	5.13	7.85
Net Cash Flow	-5.36	6.62	0.37	1.77	6.8
Cash Interest Paid	0	0	0	0	0
Cash Income Tax Paid	-2.76	-2.09	-1.38	-0.26	-0.15
Levered Free Cash Flow	-3.34	-3.11	-1.52	-1.82	-0.4
Unlevered Free Cash Flow	-3.34	-3.11	-1.52	-1.82	-0.4
Change in Working Capital	1.36	0.28	1.05	0.3	-0.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.